Is PMOS the Same as PCOS? Yes — Here Is Exactly What Changed

If you found this because a clinic letter, a forum post or a pharmacy label used a word you had never seen before, that is the whole answer. One condition. One new name. Nothing behind it moved.

What actually happened in June 2026

On 6 June 2026, The Lancet published the result of a multistep global consensus process that renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome. Funding and governance ran through 56 academic, clinical and patient organisations. Iterative global surveys collected responses from 14,360 people with the condition and health professionals across every world region, and the wording was settled through modified Delphi rounds and structured workshops.

The paper describes the condition it renamed as affecting roughly one in eight women — the same condition, at the same prevalence, under a different label.

The consortium was explicit that it wanted evolution rather than transformation. There is a transition period, an education programme, and work to align health systems and disease classification with the new term. There is no hard switchover date after which “PCOS” becomes wrong.

Why “polycystic” was the wrong word

The core objection is that the old name described something that is not actually there.

What an ultrasound counts in this condition are antral follicles — small, ordinary, arrested follicles — not pathological cysts. The renaming papers state it flatly: there is no increase in abnormal ovarian cysts. The name implied a pathology that the scan does not show.

Two further problems compounded it:

• The ovarian feature is optional. Diagnosis requires two of three features, so it is entirely possible to meet the Rotterdam criteria without any ovarian finding at all. A name built on an optional feature will mislead a proportion of the people it is applied to.
• The old name hid everything else. The 2023 international guideline strengthened recognition of metabolic risk factors, cardiovascular disease, sleep apnoea, a very high prevalence of psychological features, and elevated risk during pregnancy. None of that is suggested by the word “polycystic”.

This was not a decision imposed on patients. In the international survey published in EClinicalMedicine in 2025, 85.6% of patients and 76.1% of health professionals agreed the name should be changed, between 59% and 90% agreed with the listed advantages of changing it, and fewer than 27% agreed with any of the listed disadvantages. “Endocrine” and “metabolic” were the terms with the highest support for inclusion in a replacement — 86.2% of patients backed them in the 2023 round.

What changed, and what did not

Element	Status after June 2026	Changed?
The condition itself	Identical. Same underlying endocrine and metabolic dysfunction	No
Diagnostic criteria	Rotterdam, two of three features, per the 2023 guideline	No
Your existing diagnosis	Still valid. No reassessment triggered by the rename	No
Treatment and medication	Unchanged. The 2023 guideline remains the reference standard	No
Your phenotype	Same combination of features, same label	No
Lab tests and imaging	Same tests, same thresholds, same interpretation	No
The name	Polyendocrine metabolic ovarian syndrome (PMOS)	Yes
Disease classification	ICD coding and reclassification beyond the ovary — in progress, not complete	In progress
Everyday usage	Both terms in circulation during the transition period	In progress

Do you need a new diagnosis or a new test?

No. The rename did not touch the criteria, so a diagnosis made under the old name is a diagnosis under the new one.

The 2023 International Evidence-based Guideline is still the reference standard for how the diagnosis is made — 254 recommendations and practice points, developed with 39 professional and consumer organisations across 71 countries. Its diagnostic updates predate the rename by three years and are unaffected by it.

Feature	What it means	Changed by the rename?
Irregular cycles or anovulation	Cycles that are infrequent, absent, or not releasing an egg	No
Hyperandrogenism	Raised androgens on bloods, or clinical signs such as hirsutism	No
Polycystic ovarian morphology	Follicle count or volume on ultrasound — or, in adults only, AMH as an alternative	No

If you want the full version of how the threshold is applied, read the PMOS diagnosis criteria in detail.

Does it change your phenotype?

No. The two-of-three structure produces the same set of possible feature combinations it always did, and the rename neither merges, splits nor renumbers them. If you were told you have the non-ovarian, hyperandrogenic pattern, that is still what you have, and the management advice attached to it is unchanged.

That matters because advice on this site is phenotype-segmented rather than name-segmented. What you do about insulin resistance, androgens or irregular cycles depends on which features you have, not on which of the two names your clinic happens to be using this month.

Does it change anything for teenagers?

The adolescent criteria are unchanged, and they were already stricter than the adult ones. Diagnosis before adulthood requires both irregular cycles and hyperandrogenism, with the ovarian criterion excluded entirely because follicle counts overlap too heavily with normal puberty. A 2026 review of the rename for adolescent care puts the prevalence in this age group at approximately 6.3% worldwide and confirms the criteria are carried across intact.

What each word in the name is doing

• Polyendocrine — more than one hormonal system is involved, not the ovary alone.
• Metabolic — insulin resistance and cardiometabolic risk are core features, not side notes.
• Ovarian — the ovary is still involved; it is just no longer the whole story.
• Syndrome — a cluster of features, diagnosed by pattern, not by a single test.

The consensus paper notes that accuracy improved by two moves: dropping “cysts”, and naming the endocrine, metabolic and ovarian dysfunction together. The acronym was deliberately not preserved — an accurate name was prioritised over keeping “PCOS” recognisable. For the fuller story of how that decision was reached, see why PCOS was renamed.

Which word should you use?

Use whichever one the person in front of you will understand.

• Talking to a clinician: say “PCOS, now called PMOS” for the next year or two. It removes any ambiguity in either direction.
• Searching for information: search both. Almost everything written before mid-2026 uses PCOS, including the guideline your treatment is based on.
• Insurance, referrals, sick notes: PCOS is still what appears in most coding systems. The reclassification work is under way, not finished.
• Reading a new paper: expect PMOS, often with “formerly PCOS” alongside it.

Your next step

Do one thing this week: open your patient record or last clinic letter and note which term it uses. That is the word to lead with at your next appointment, followed by the other one.

If that appointment is coming up, read how to raise the name change with your doctor — some clinicians have not yet seen the consensus paper, and a link is more useful than an argument. For the announcement itself and what it means in practice, start with PCOS is now PMOS, then work through the rest of the diagnosis section once you know which features you actually have.